All In Biotech

Drug Trial Radar · NCT04487275

MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code)

MLC901 for Moderate to Severe Traumatic Brain Injury: Pilot, Randomized, Double-Masked, Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Jul 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 20, 2018

Primary completion

Sep 2020

Study completion Oct 2020

Sponsor

Lead sponsor
Ali Amini HarandiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with a diagnosis of moderate to severe traumatic brain injury (TBI) will be enrolled. Subjects will be randomly assigned to receive either MLC901 (Specified Drug Code) or placebo capsules three times per day over 6 months. Evaluation of patients will be carried out at baseline as well as at 3-month and 6-month follow-up visits. Modified Rankin Scale (mRS) and Glasgow outcome scale (GOS) will be used to examine patients. Efficacy will be evaluated by comparing these two scores between the 2 groups at follow-up visits.

Conditions

  • Traumatic Brain Injury

Interventions

  • MLC901 or PlaceboDrug

    groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. functional outcome 1Time frame: at baseline
  2. functional outcome 2Time frame: at 3rd month post-injury
  3. functional outcome 3Time frame: at 6th month post-injury
  4. functional outcome 4Time frame: at baseline
  5. functional outcome 5Time frame: at 3rd month post-injury
  6. functional outcome 6Time frame: at 6th month post-injury

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brain Mapping Research Center

    Tehran, Iran · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.